Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS

(REGN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Regeneron Pharmaceuticals : Says FDA Approves Eylea Injection for All Diabetic Retinopathy Treatment

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/13/2019 | 03:15pm EDT

By Michael Dabaie

Regeneron Pharmaceuticals Inc. (REGN) said the Food and Drug Administration approved Eylea injection to treat all stages of diabetic retinopathy.

The company said Eylea improves diabetic retinopathy and prevents worsening disease that can lead to blindness. Diabetic retinopathy is the leading cause of blindness among working-aged American adults, Regeneron said.

The FDA approval of Eylea as a treatment for diabetic retinopathy was based on six-month and one-year results from Panorama, a randomized, multi-center, controlled Phase 3 trial that enrolled 402 patients.

Write to Michael Dabaie at michael.dabaie@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
07:00aREGENERON PHARMACEUTICALS : Educational Campaign Helps Teens and Their Caregiver..
PR
09/17REGENERON PHARMACEUTICALS : Debuts on Prestigious Dow Jones Sustainability World..
PR
09/06REGENERON PHARMACEUTICALS : U.S. Court Dismisses Novartis Patent Infringement Su..
PU
08/29REGENERON PHARMACEUTICALS : U.S. District Court Invalidates Amgen Patent Claims ..
AQ
08/29GLOBAL MARKETS LIVE : Dell, United Airlines, UBS, Apple…
08/28U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight
RE
08/28REGENERON PHARMACEUTICALS : U.S. District Court Invalidates Amgen Patent Claims ..
PR
08/28US Judge Mostly Sets Aside Jury Ruling on Repatha Patents -Reuters
DJ
08/28U.S. Federal Judge Rules for Sanofi, Regeneron in Long-Running Patent Dispute..
DJ
08/15REGENERON PHARMACEUTICALS : Announces Upcoming Investor Conference Presentation
PR
More news
Financials (USD)
Sales 2019 7 653 M
EBIT 2019 2 274 M
Net income 2019 1 989 M
Finance 2019 4 884 M
Yield 2019 -
P/E ratio 2019 16,5x
P/E ratio 2020 13,7x
EV / Sales2019 3,48x
EV / Sales2020 2,92x
Capitalization 31 527 M
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 381,85  $
Last Close Price 288,12  $
Spread / Highest target 72,2%
Spread / Average Target 32,5%
Spread / Lowest Target 8,64%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
Michael S. Brown Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS-22.86%31 527
GILEAD SCIENCES5.79%83 801
VERTEX PHARMACEUTICALS6.21%45 238
GENMAB27.73%13 120
NEUROCRINE BIOSCIENCES, INC.42.01%9 287
HUALAN BIOLOGICAL ENGINEERING INC--.--%6 518